Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Evaluation of serum mesothelin in malignant and benign ovarian masses.

Ibrahim M, Bahaa A, Ibrahim A, El Hakem AA, Abo-El Noor A, El Tohamy U.

Arch Gynecol Obstet. 2014 Jul;290(1):107-13. doi: 10.1007/s00404-014-3147-2. Epub 2014 Jan 21.

PMID:
24445964
2.

Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.

Aktas B, Kasimir-Bauer S, Wimberger P, Kimmig R, Heubner M.

Anticancer Res. 2013 Jan;33(1):329-36.

PMID:
23267165
3.

Diagnostic value of serum kallikrein-related peptidases 6 and 10 versus CA125 in ovarian cancer.

El Sherbini MA, Sallam MM, Shaban EA, El-Shalakany AH.

Int J Gynecol Cancer. 2011 May;21(4):625-32. doi: 10.1097/IGC.0b013e31821283c3.

PMID:
21412167
4.

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Chinese.

PMID:
19134334
5.

Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer.

Wu X, Li D, Liu L, Liu B, Liang H, Yang B.

Arch Gynecol Obstet. 2014 Jun;289(6):1309-14. doi: 10.1007/s00404-013-3128-x. Epub 2013 Dec 27.

PMID:
24370956
6.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

7.

Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.

Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC Jr, Mills GB.

Cancer. 1995 Nov 1;76(9):1615-20.

8.

HE4 can help discriminate women with malignant ovarian 
tumors only if CA125 levels are elevated.

Pitta Dda R, Sarian LO, Campos EA, Andrade LL, Sallum LF, Bragança JF, Campos Cde M, Derchain S.

Int J Biol Markers. 2013 Oct-Dec;28(4):e377-86.

PMID:
23828407
9.

Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?

Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW.

Lung Cancer. 2013 Apr;80(1):39-44. doi: 10.1016/j.lungcan.2012.12.008. Epub 2013 Jan 26.

PMID:
23357461
10.

Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.

Robati M, Ghaderi A, Mehraban M, Shafizad A, Nasrolahi H, Mohammadianpanah M.

Arch Gynecol Obstet. 2013 Oct;288(4):859-65. doi: 10.1007/s00404-013-2819-7. Epub 2013 Apr 7.

PMID:
23564055
11.

Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.

Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK.

Clin Cancer Res. 2002 Oct;8(10):3193-7.

13.

Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.

Camlica H, Duranyildiz D, Tas F, Yasasever V.

Am J Clin Oncol. 2008 Dec;31(6):585-8. doi: 10.1097/COC.0b013e318174dbd2.

PMID:
19060592
14.

Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72. doi: 10.1158/1055-9965.EPI-08-1034.

15.

HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.

Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN.

Asian Pac J Cancer Prev. 2010;11(1):111-6.

16.

Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.

Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1127-33. doi: 10.1158/1055-9965.EPI-08-0653. Epub 2009 Mar 31.

17.

[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].

Wang MJ, Qi J, Wang H, Li XX, Wei BJ, Fu C, Gao J, Han BB.

Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):540-3. Chinese.

PMID:
22093635
18.

Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?

Azzam AZ, Hashad DI, Kamel NA.

Arch Gynecol Obstet. 2013 Jul;288(1):167-72. doi: 10.1007/s00404-013-2722-2. Epub 2013 Jan 30.

PMID:
23361457
19.

The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.

Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J.

Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.

PMID:
22214964
20.

Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.

Kristjansdottir B, Levan K, Partheen K, Sundfeldt K.

Gynecol Oncol. 2013 Oct;131(1):52-8. doi: 10.1016/j.ygyno.2013.07.094. Epub 2013 Jul 25.

Supplemental Content

Support Center